Pfizer, Beam Therapeutics Form Multi-Target Research Collaboration
2022年1月10日 - 8:48PM
Dow Jones News
By Colin Kellaher
Pfizer Inc. and Beam Therapeutics Inc. on Monday said they
formed an exclusive four-year research collaboration focused on
in-vivo base editing programs for three targets aimed at rare
genetic diseases of the liver, muscle and central nervous
system.
As part of the collaboration, New York drugmaker Pfizer will
make an upfront payment of $300 million to Beam, a Cambridge,
Mass., biotechnology company.
The companies said Beam is also eligible for up to $1.05 billion
in potential milestone payments, assuming Pfizer exercises its
opt-in license rights for all three targets, along with royalties
on product sales.
The companies said Beam will conduct all research activities
through development candidate selection for three undisclosed
targets that aren't included in Beam's existing programs, while
Pfizer can opt in to exclusive, worldwide licenses to each
candidate, after which it will be responsible for all development
activities, as well as potential regulatory approvals and
commercialization.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 10, 2022 06:33 ET (11:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024
